Dominici, M, Tadjali, M, Kepes, S, Allay, ER, Boyd, K, Ney, PA et al.. Transgenic mice with pancellular enhanced green fluorescent protein expression in primitive hematopoietic cells and all blood cell progeny. Genesis 42: 17-22

Division of Experimental Hematology, Department of Hematology and Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
genesis (Impact Factor: 2.02). 05/2005; 42(1):17-22. DOI: 10.1002/gene.20121
Source: PubMed


Transgenic mice homogeneously expressing enhanced green fluorescence protein (EGFP) in primitive hematopoietic cells and all blood cell progeny, including erythrocytes and platelets, have not been reported. Given previous data indicating H2Kb promoter activity in murine hematopoietic stem cells (HSCs), bone marrow (BM), and lymphocytes, an H2Kb enhancer/promoter EGFP construct was used to generate transgenic mice. These mice demonstrated pancellular EGFP expression in both primitive BM Sca-1+Lin-Kit+ cells and side population (SP) cells. Additionally, all peripheral blood leukocytes subsets, erythrocytes, and platelets uniformly expressed EGFP strongly. Competitive BM transplantation assays established that transgenic H2Kb-EGFP HSCs had activity equivalent to wildtype HSCs in their ability to reconstitute hematopoiesis in lethally irradiated mice. In addition, immunohistochemistry revealed EGFP transgene expression in all tissues examined. This transgenic strain should be a useful reagent for both murine hematopoiesis studies and functional studies of specific cell types from particular tissues.

Download full-text


Available from: Massimo Dominici, Sep 28, 2014
  • Source
    • "Several groups performed reconstitution assays using bone marrow cells ectopically expressing the JAK2 V617F mutant and showed that mice indeed developed hallmarks of PV.22-24 Shortly after, Shide et al. and Xing et al. generated stable transgenic mouse models expressing the mouse JAK2 V617F cDNA under control of the major histocompatibility complex H-2Kb promoter25 or the human JAK2 V617F cDNA under control of the Vav promoter,26 respectively. Both H-2Kb and Vav promoters drive transgene expression efficiently throughout the nucleated hematopoietic cell types27,28 and both groups demonstrated that the mice developed key features of PV or ET with erythrocytosis and thrombocytosis.25,26 Interestingly, a later study used a floxed version of the human JAK2 V617F cDNA under control of a human JAK2 promoter and showed that the disease outcome correlates with the relative expression levels of endogenous wild type (wt) vs. human mutant JAK2.29 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Janus kinases (JAKs) are non-receptor tyrosine kinases essential for activation of signaling mediated by cytokine receptors that lack catalytic activity, including receptors for erythropoietin, thrombopoietin, most interleukins and interferon. Upon hormone binding, JAKs phosphorylate tyrosine residues in the receptor cytoplasmic domains and in JAKs themselves leading to recruitment and activation of downstream signaling proteins such as signal transducer and activator of transcription (STAT). The JAK-STAT pathway is important for functional hematopoiesis and several activating mutations in JAK proteins have recently been described as underlying cause of blood disorders. One of the best studied examples is the JAK2 V617F mutant which is found in 95% of polycythemia vera patients and 50% of patients suffering from essential thrombocythemia and primary myelofibrosis. Much effort has been made to understand how the JAK2 V617F affects hematopoietic stem cell (HSC) renewal and lineage differentiation, since convincing evidence has been provided to support the notion that the mutation is acquired at the HSC level. We discuss several in vivo models that support contrary conclusions with respect to the advantage given to HSCs by JAK2 V617F. Moreover, we provide the current knowledge about STAT5 activation and its link to HSC expansion as well as amplification of the erythroid compartment. Evidence for both JAK2 V617F mutated HSCs exhibiting skewed differentiation potential and for amplification occurring after erythroid commitment has been provided, and we will discuss whether this evidence is relevant for the disease.
    07/2012; 1(3):184-190. DOI:10.4161/jkst.22071
  • Source
    • "To investigate the role of S100A9 in myeloid cell differentiation in vivo, we generated transgenic mice (S100A9Tg) that overexpress S100A9 in hematopoietic cells under control of the H2K-promoter/enhancer and Moloney MuLV enhancer/poly(A) site (34). This promoter previously demonstrated high-level expression of targeted cDNA in hematopoietic cells from spleens, lymph nodes, and thymus (34), as well as in HPCs and stem cells in bone marrow (35). To better trace the expression of the transgene transcript, GFP was linked to the S100A9 cDNA behind an IRES sequence to permit independent translation (Fig. 4 A). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Accumulation of myeloid-derived suppressor cells (MDSCs) associated with inhibition of dendritic cell (DC) differentiation is one of the major immunological abnormalities in cancer and leads to suppression of antitumor immune responses. The molecular mechanism of this phenomenon remains unclear. We report here that STAT3-inducible up-regulation of the myeloid-related protein S100A9 enhances MDSC production in cancer. Mice lacking this protein mounted potent antitumor immune responses and rejected implanted tumors. This effect was reversed by administration of wild-type MDSCs from tumor-bearing mice to S100A9-null mice. Overexpression of S100A9 in cultured embryonic stem cells or transgenic mice inhibited the differentiation of DCs and macrophages and induced accumulation of MDSCs. This study demonstrates that tumor-induced up-regulation of S100A9 protein is critically important for accumulation of MDSCs and reveals a novel molecular mechanism of immunological abnormalities in cancer.
    Journal of Experimental Medicine 10/2008; 205(10):2235-49. DOI:10.1084/jem.20080132 · 12.52 Impact Factor
  • Source

Show more